Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase-Reference-Cited by-同舟云学术

Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase

Published:2003-12-04 Issue:12 Volume:98 Page:2636-2642
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.,O'Brien Susan,Cortes Jorge,Giles Francis J.,Rios Mary Beth,Shan Jianqin,Faderl Stefan,Garcia-Manero Guillermo,Ferrajoli Alessandra,Verstovsek Srdan,Wierda William,Keating Michael,Talpaz Moshe

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference39 articles.

1. Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]

2. Chronic Myelogenous Leukemia: Biology and Therapy

3. The Biology of Chronic Myeloid Leukemia

4. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase [see comments]

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The potential of phytochemicals against epidermal growth factor receptor tyrosine kinase (EGFRK): an insight from molecular dynamic simulations;Journal of Biomolecular Structure and Dynamics;2023-05-08

2. Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience;Leukemia & Lymphoma;2021-03-16

3. Deleterious reproductive effects of nilotinib in mouse model;Reproduction;2021-03

4. Kronik Miyeloid Lösemide İmatinib Mesilat Tedavisi;Sakarya Medical Journal;2020-03-16

5. Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis;European Journal of Cancer;2018-11